ライフサイエンスコーパス: CRT

1 CRT deficiency alters the distributions of ATZ-ER chaper

2 CRT implantation according to standard of care.

3 CRT knockdown activates p53, which mediates cell-death r

4 CRT localized around tight junctions (TJs) of T84 IECs.

5 CRT may be a highly effective treatment strategy in mrTD

6 CRT patients were <21 years of age or had congenital hea

7 CRT reduced the rate of onset of new ventricular arrhyth

8 CRT was administered with a 1.0-cm clinical target volum

9 CRT was associated with markedly reduced risk of heart t

10 CRT was knocked down or overexpressed in T84 cells, whic

11 CRT was programmed off after LVAD implant in 44 patients

12 CRT-knockout organoids also had diminished barrier forma

13 CRT-related grade 3 or 4 toxicity was lower (37% v 27%)

14 ncidence of severe POM (9.6% SC-TNT vs 12.0% CRT, P = 0.46) or overall POM (39.7% SC-TNT vs 37.5% CRT

15 ammatory drug (NSAID) monotherapy (n = 157), CRT increased 5.7 +/- 18.4 mum in nondiabetic patients c

16 vival were not different between IMRT and 3D-CRT.

17 onformal external beam radiation therapy (3D-CRT) have not been compared prospectively.

18 and 34.8% of non-naive patients had a week-4 CRT that was >35 mum thicker than the earlier occuring l

19 0.46) or overall POM (39.7% SC-TNT vs 37.5% CRT, P = 0.64) between cohorts.

20 d females in 1093 healthy individuals and 50 CRT patients using electrophysiological computer models

21 roid and NSAID combination therapy (n = 55), CRT increased 3.6 +/- 4.1 mum in nondiabetic patients co

22 In eyes with steroid monotherapy (n = 64), CRT increased 38.1 +/- 72.8 mum in nondiabetic patients

23 We retrospectively analyzed 946 CRT patients with conduction delay.

24 Among 5,954 CRT-D-implanted patients, after multivariable adjustment

25 in patients eligible for implantation with a CRT with defibrillator (CRT-D).

26 M negative and no ECE, 47% received adjuvant CRT.

27 ADVANCE CRT exposes a vulnerable group of heart failure patients

28 e in the prospective, international, ADVANCE CRT registry (Advance Cardiac Resynchronization Therapy

29 Resynchronization Therapy Registry [ADVANCE CRT]; NCT01805154).

30 icular ejection fraction (LVEF) change after CRT.

31 group B for consolidation chemotherapy after CRT.

32 0.30; 95% CI: 0.12 to 0.78) were lower after CRT-D than after CRT-P in +MWF but not in -MWF.

33 athy and were followed up for 6 months after CRT implantation.

34 2 to 0.78) were lower after CRT-D than after CRT-P in +MWF but not in -MWF.

35 ival in the ITT and PP analyses at 3 y after CRT.

36 Also, among all CRT-D-implanted patients, the authors compared outcomes

37 We analyzed CRT patients from Cleveland Clinic and Johns Hopkins.

38 onization therapy (CRT) pacemakers (4%), and CRT defibrillators (17%), as well as abandoned leads (2%

39 OCTA biomarkers and the changes of BCVA and CRT after treatment.

40 nd between changes from baseline in BCVA and CRT in pooled AMD trial data.

41 Treatment with IC and CRT resulted in excellent outcomes.

42 surgery, BCVA was 62.2 and 56.9 letters and CRT was 342 mum and 301 mum in the laser control and IAI

43 were no differences between the CRT OFF and CRT ON groups in overall mortality (Log rank p = 0.32, a

44 650), 963 outpatient adult courses of RT and CRT started from January 7 to June 30, 2019, were evalua

45 ccurately triaged patients undergoing RT and CRT, directing clinical management with reduced acute ca

46 n received chemotherapy, second surgery, and CRT.

47 ulation with mutated EGFR receiving TKIs and CRT.

48 differences between the results of RCTs and CRTs on the same topic are given.

49 the magnitude of the reduction from baseline CRT at 12 months tended to increase linearly with increa

50 nificant electrical dyssynchrony, all before CRT implant.

51 nts underwent endomyocardial biopsies before CRT implantation, with histological quantification of fi

52 del predicted that targeted induction before CRT, an approach currently being tested in clinical tria

53 are important conceptual differences between CRTs and RCTs relating to design, analysis, and inferenc

54 vant to substrate recruitment and folding by CRT.

55 ) with cisplatin and gemcitabine followed by CRT.

56 y trafficking of ATZ and their regulation by CRT could lead to new therapies for lung and liver disea

57 rrier family 6 member 8 (SLC6A8, also called CRT) in intestinal epithelial cells (IECs) and mice, and

58 Calreticulin (CRT) is a high-capacity Ca2+ protein whose expression is

59 (ROS) and surface exposure of calreticulin (CRT).

60 We now show that calreticulin (CRT), an endoplasmic reticulum (ER) glycoprotein chapero

61 ts with chemotherapy-induced cardiomyopathy, CRT was associated with improvement in LVEF after 6 mont

62 mic chemotherapy followed by chemoradiation (CRT), addresses both occult metastases and positive marg

63 day (FCT) is an established chemoradiation (CRT) regimen for selective bladder-sparing treatment of

64 patient radiotherapy (RT) or chemoradiation (CRT) frequently require acute care (emergency department

65 do not benefit from standard chemoradiation (CRT) is an important medical need.

66 ng of surgery followed by chemoradiotherapy (CRT) for oral cavity cancers and primary CRT for pharynx

67 ith definitive concurrent chemoradiotherapy (CRT) after IC and 54% (95% CI, 44% to 61%) after definit

68 SUMMARY BACKGROUND DATA: Chemoradiotherapy (CRT) response is a predictor of survival in rectal cance

69 ated with curative-intent chemoradiotherapy (CRT).

70 st-treatment MRIs in post-chemoradiotherapy (CRT) patients, mrTD/mrEMVI status was again the only sig

71 cheduling of preoperative chemoradiotherapy (CRT) and chemotherapy remains to be established.

72 At 1 mo after terminating chemoradiotherapy (CRT), no differences were observed in the incidence of g

73 This single-center study compared CRT patients (implant date, 2004-2017) and controls, mat

74 in patients who were treated with concurrent CRT after IC and 39% (95% CI, 30% to 46%) in patients wh

75 We enrolled 612 consecutive CRT patients and FBC was measured within 24 hours prior

76 omplete response (CR) received consolidation CRT to 64 Gy and others underwent cystectomy.

77 e (LVAD) implant vary: some centers continue CRT while others turn off the left ventricular (LV) lead

78 We sought to study the effect of continued CRT versus turning off CRT pacing following continuous f

79 (CRT) either do not respond to conventional CRT or remain untreated due to an inability or impedimen

80 g chemotherapeutic switch before long-course CRT and subsequent resection.

81 llment in clinical trials means that current CRT guidelines may be biased toward males.

82 r, the efficacy of CRT with a defibrillator (CRT-D) may be modified after the development of the firs

83 implantation with a CRT with defibrillator (CRT-D).

84 hieve a favorable response to IC, definitive CRT results in improved survival compared with those who

85 c heart failure and electrical dyssynchrony, CRT was associated with improved heart transplant-free s

86 lly improved prediction of echocardiographic CRT response and survival beyond guidelines.

87 Here, we review emerging CRT technologies and assess their therapeutic potential

88 t of 295 patients with LVAD and pre-existing CRT was studied.

89 underwent standard and 46 patients extended CRT.

90 were compared with those undergoing extended CRT (54 Gy and 6 cycles of 5-FU-based chemotherapy).

91 Patients undergoing extended CRT were more likely to undergo organ preservation and a

92 ict 9-13 ms lower QRSd thresholds for female CRT guidelines.

93 accounting for the smaller LV size in female CRT patients predict 9-13 ms lower QRSd thresholds for f

94 ultiple regression model with adjustment for CRT and ellipsoid zone disruption (P < 0.001).

95 cing may serve as a valuable alternative for CRT.

96 l patient selection should be considered for CRT-D implantation in patients with non-LBBB conduction.

97 ons predicted female-specific guidelines for CRT, which were 9-13 ms lower than current guidelines.

98 nd hence predict sex-specific guidelines for CRT.

99 Indications for CRT were wider than past trials.

100 and right ventricular pacing 5) referred for CRT in addition to LV lead.

101 These findings indicate a novel role for CRT in promoting the secretory trafficking of a protein

102 arameters in enhancing patient selection for CRT implantation should be conducted to confirm our find

103 of IEC cell lines and colonoids derived from CRT-knockout mice, we found that CRT regulates energy ba

104 Up-front CRT followed by chemotherapy resulted in better complian

105 However, after occurrence of a first HHF, CRT-D therapy was associated with a pronounced 44% reduc

106 HOT-CRT may improve clinical and echocardiographic outcomes

107 e, during HBP, biventricular pacing, and HOT-CRT was measured.

108 Conclusions In this feasibility cohort, HOT-CRT resulted in improved electrical resynchronization.

109 tricular (LV) pacing (His-Optimized CRT [HOT-CRT]) to maximize electrical resynchronization.

110 0001), and further to 120+/-16 ms during HOT-CRT ( P<0.0001).

111 Results HOT-CRT was successful in 25 of 27 patients (age 72+/-15 yea

112 However, CRT management following continuous flow Left Ventricula

113 machine learning of ECG waveforms identified CRT subgroups with relevance beyond LBBB and QRSd.

114 achine learning of ECG waveforms to identify CRT subgroups that may differentiate outcomes beyond QRS

115 The aim of the study was to determine if CRT could be optimized by sequential HBP followed by lef

116 (SD, 8.0 ETDRS letters), and mean change in CRT was -175.38 mum (SD, 132.62 mum).

117 Corresponding change in CRT was a modest increase to 364 mum (P > 0.05 compared

118 Diabetic patients showed less change in CRT when compared to controls in steroid monotherapy.

119 nistic explanation for the sex difference in CRT response.

120 mepoints, with no significant differences in CRT reduction or adverse effect rates.

121 We aimed to test if sex differences in CRT response at lower QRSd thresholds are explained by d

122 ication of bundle branch block morphology in CRT.

123 0 and 2013, the authors compared outcomes in CRT-eligible patients implanted with CRT-D versus ICD-on

124 f LVs with BiV and His bundle (HB) pacing in CRT patients.

125 s of the protein transport protein Sec31A in CRT-deficient cells.

126 l-cause mortality and/or heart transplant in CRT patients.

127 Despite a modest worsening in CRT after cataract surgery, BCVA was improved in both tr

128 verity of psychopathology, duration of index CRT episode, first contact with services, and diagnosis

129 erwent transurethral resection and induction CRT to 40 Gy.

130 F from baseline to 6 months after initiating CRT.

131 GF-beta receptor signaling for intracellular CRT (iCRT)-dependent induction of TGF-beta1 and ECM prot

132 Our study identifies intracellular CRT as an important therapeutic target for tumors whose

133 Among non-LBBB CRT-D-eligible patients, CRT-D implantation was associat

134 In 11,505 non-LBBB CRT-eligible patients, after multivariable adjustment, a

135 hy, non-left bundle branch block, and lower %CRT pacing vs. responders).

136 mum thicker than the earlier occuring lowest CRT value (nadir).

137 In MADIT-CRT, we show a beneficial effect of CRT-D in patients wi

138 urrent HHF in patients without LBBB in MADIT-CRT.

139 ion in risk of a HF event/death in the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantat

140 Following PSM, 63 matched CRT-control pairs were identified with no significant di

141 Optimal dosing interval for maximal CRT reduction may be less than 4 weeks for a significant

142 Only 35.4% of patients had maximal CRT reduction at 4 weeks.

143 Two-thirds (64.6%) reached maximal CRT reduction earlier than the standard 4-week interval:

144 The time to maximal CRT reduction was not related to axial length, age, lens

145 , mean BCVA was 61.5 ETDRS letters, and mean CRT was 464.81 mum.

146 paired baseline and 12-month readings, mean CRT declined from 320 to 271 mum (mean change, -48 mum),

147 1 wild-type mouse embryo fibroblasts (MEFs), CRT null MEFs were unresponsive.

148 Among patients with NICD and a QRS >=150 ms, CRT-D was associated with decreased mortality at 3 years

149 c cT2N0 rectal cancer managed by neoadjuvant CRT were retrospectively reviewed.

150 owed a superior effectiveness of neoadjuvant CRT and surgery compared with surgery alone (HR = 0.77,

151 vant SC-TNT is an alternative to neoadjuvant CRT for rectal cancer.

152 to develop complete response to neoadjuvant CRT.

153 ontrol, respectively) and 390 (63.5%) had no CRT (187 and 203 randomized to TMVr and control, respect

154 There was no CRT procedural mortality and 1 system infection at 54 mo

155 cretory trafficking of ATZ in the absence of CRT is coincident with enhanced accumulation of ER-deriv

156 However, a survival benefit of CRT in this population has not been established.

157 Among patients without LBBB, the benefit of CRT-D was nonsignificant for the first HHF (hazard ratio

158 Organoids from colon cells of CRT-knockout mice and control mice were analyzed by qRT-

159 The longer interval between completion of CRT and surgery in group B (median 90 v 45 days in group

160 In MADIT-CRT, we show a beneficial effect of CRT-D in patients without LBBB subsequent to development

161 We aimed to study the effect of CRT-D on long-term risk of recurrent HHF in patients wit

162 However, the efficacy of CRT with a defibrillator (CRT-D) may be modified after t

163 y, we identify a novel, critical function of CRT as a cell survival factor in multiple types of human

164 This study aimed to evaluate the impact of CRT upon heart transplant-free survival in pediatric and

165 The clinical importance of CRT expression was revealed in the analysis of the large

166 A high incidence of CRT nonresponders persists despite good patient selectio

167 = 2,058) to demonstrate that high levels of CRT inversely correlates with patient survival.

168 from patients with IBD had reduced levels of CRT messenger RNA compared with those from control indiv

169 nactive Crohn's disease have lower levels of CRT, which might contribute to the reduced barrier funct

170 ion beyond well-known clinical predictors of CRT response (likelihood ratio test P<0.001).

171 the overall median risk-standardized rate of CRT-D use was 79.9% (range, 26.7%-100%; median OR, 2.08;

172 anistically, we show that down-regulation of CRT results in mitochondrial Ca2+ overload and induction

173 ally dependent on the glycan-binding site of CRT, which is generally relevant to substrate recruitmen

174 The challenges facing the translation of CRT into the clinic are discussed.

175 The use of CRT varied substantially according to several factors, i

176 However, use of CRT-D differed by race and implanting operator character

177 Our study suggests that turning off CRT pacing after LVAD implantation in patients with prev

178 e effect of continued CRT versus turning off CRT pacing following continuous flow LVAD implantation.

179 left ventricular (LV) pacing (His-Optimized CRT [HOT-CRT]) to maximize electrical resynchronization.

180 y, patients who received a first-time ICD or CRT-D device from any of the 4 major manufacturers (Janu

181 age, 65 years; 29.6% women) received ICD or CRT-D devices from the 4 manufacturers implanted by 4435

182 Patients were more likely to receive ICD or CRT-D devices from the manufacturer that provided the hi

183 ent to the physician who performed an ICD or CRT-D implantation than each other manufacturer individu

184 yments to physicians who performed an ICD or CRT-D implantation.

185 ectional study, a large proportion of ICD or CRT-D implantations were performed by physicians who rec

186 re treated with surgery plus radiotherapy or CRT (adjusted hazard ratio of 5.68 [95% CI, 2.89 to 9.36

187 ve surgery and postoperative radiotherapy or CRT after IC (log-rank P = .001).

188 nonmetastatic rectal cancer after SC-TNT or CRT between 2010 and 2018.

189 oxaliplatin before fluorouracil/oxaliplatin CRT (50.4 Gy) or to group B for consolidation chemothera

190 Among non-LBBB CRT-D-eligible patients, CRT-D implantation was associated with better outcomes c

191 ate analysis revealed that in LBBB patients, CRT-D, compared with implantable cardioverter-defibrilla

192 Patients underwent a 3-month post-CRT positron emission tomography/computed tomography sca

193 ng patients received immediate postoperative CRT after near-total resection or GTR.

194 of age who received immediate postoperative CRT and for older patients is similar.

195 ion/GTR groups given immediate postoperative CRT, respectively.

196 whether machine learning (ML) could predict CRT response beyond current guidelines.

197 ML models were developed to predict CRT response using different combinations of classificat

198 need to identify better variables to predict CRT response.

199 LVAD implantation in patients with previous CRT pacing did not affect mortality, heart transplantati

200 py (CRT) for oral cavity cancers and primary CRT for pharynx and larynx cancers.

201 Among 614 patients, 224 (36.5%) had prior CRT (115 and 109 randomized to TMVr and control, respect

202 aximally tolerated GDMT, regardless of prior CRT implantation.

203 We sought to examine the effect of prior CRT in patients enrolled in COAPT.

204 Outcomes were assessed according to prior CRT use.

205 sus control treatment in patients with prior CRT (48.6% versus 67.2%, hazard ratio, 0.60 [95% CI, 0.4

206 transplant or death occurred in 12 (19%) PSM-CRT subjects and 37 (59%) PSM-controls with a median fol

207 with concurrent chemotherapy and radiation (CRT) to improve outcomes in genotype-defined cancers rem

208 se assessment following (chemo)radiotherapy (CRT) for head and neck squamous cell carcinoma (HNSCC).

209 riable adjustment, among patients with RBBB, CRT-D was not associated with better outcomes, compared

210 emale, ischemic disease 39%), 74.3% received CRT-defibrillator devices, using mainly quadripolar LV l

211 of 63506 eligible patients (88.6%) received CRT-D at the time of device implantation.

212 (38%) received SC-TNT and 259 (62%) received CRT.

213 420 patients (75%) received CRT and 142 (25%) had radiotherapy alone.

214 ved upfront surgery and 584 (55.9%) received CRT.

215 patients with stage I to III SCCAC received CRT including cisplatin, fluorouracil, and radiation the

216 Of 133 patients who received CRT during the study period, 84 met all study inclusion

217 fibrillator compared with those who received CRT without a defibrillator (hazard ratio for mortality

218 with ICM had better survival when receiving CRT with a defibrillator compared with those who receive

219 Several examples of recent CRTs of community and intensive care unit infection prev

220 in advanced heart failure patients requiring CRT.

221 oral Blocker Therapy in Optimally Responding CRT Patients [STOP-CRT]; NCT02200822).

222 val is similar between extended and standard CRT groups at 5 years (78% vs 56%; P = 0.12).

223 splatin and gemcitabine followed by standard CRT with weekly cisplatin plus pelvic radiotherapy or to

224 atin plus pelvic radiotherapy or to standard CRT alone.

225 ing of cisplatin and gemcitabine to standard CRT is not superior and is possibly inferior to CRT alon

226 Patients undergoing standard CRT (50.4 Gy and 2 cycles of 5-FU-based chemotherapy) we

227 y in Optimally Responding CRT Patients [STOP-CRT]; NCT02200822).

228 erived from CRT-knockout mice, we found that CRT regulates energy balance in IECs and thereby epithel

229 T knockdown or overexpression, we found that CRT regulates intracellular creatine, barrier formation,

230 The CRT-D versus implantable cardioverter-defibrillator-only

231 The CRT-related chaperone calnexin does not enhance ATZ secr

232 combined the pre-vaccine time period and the CRT time period, using outcomes from control-only villag

233 There were no differences between the CRT OFF and CRT ON groups in overall mortality (Log rank

234 ith 3-year PFS rates of 40.9% v 60.4% in the CRT arm (hazard ratio, 1.84; 95% CI, 1.04 to 3.26; P = .

235 s were 56.3% in the NAC arm and 80.3% in the CRT arm (P = .008).

236 In the CRT patient cohort, model simulations predicted female-s

237 vage surgery is similar, irrespective of the CRT regimen.

238 ndomly assigned to the NAC arm and 52 to the CRT-alone arm.

239 Although chemoradiation therapy (CRT) with cisplatin remains the standard treatment of pa

240 e postoperative conformal radiation therapy (CRT).

241 - an approach termed cis-regulation therapy (CRT).

242 gible for cardiac resynchronization therapy (CRT) either do not respond to conventional CRT or remain

243 Cardiac resynchronization therapy (CRT) has significant nonresponse rates.

244 Cardiac resynchronization therapy (CRT) improves heart failure outcomes but has significant

245 Cardiac resynchronization therapy (CRT) improves outcomes in heart failure patients with wi

246 nefits of cardiac resynchronization therapy (CRT) in patients with non-left bundle branch block (LBBB

247 ackground Cardiac resynchronization therapy (CRT) is an established therapy for patients with cardiom

248 Cardiac resynchronization therapy (CRT) is an established therapy in patients with dilated

249 Cardiac resynchronization therapy (CRT) is an important treatment for heart failure.

250 ponse" to cardiac resynchronization therapy (CRT) is recognized, but definition(s) applied in practic

251 implanted cardiac resynchronization therapy (CRT) is unknown.

252 Cardiac resynchronization therapy (CRT) is usually performed by biventricular (BiV) pacing.

253 Ds (30%), cardiac resynchronization therapy (CRT) pacemakers (4%), and CRT defibrillators (17%), as w

254 Cardiac resynchronization therapy (CRT) studies in pediatric or congenital heart disease pa

255 following cardiac resynchronization therapy (CRT).

256 and seek cardiac resynchronization therapy (CRT).

257 ation; P = .282), central retinal thickness (CRT) 12.0 +/- 38.2 mum vs 5.9 +/- 15.8 mum (P = .256), c

258 acuity (BCVA) and central retinal thickness (CRT) also were obtained.

259 t increase in the central retinal thickness (CRT) and average thickness (AT) between follow-up examin

260 imal reduction of central retinal thickness (CRT) and the presence of intraretinal and subretinal flu

261 RS] letters), and central retinal thickness (CRT) from baseline to week 52.

262 ressure (IOP) and central retinal thickness (CRT) were evaluated for naive and PT DME eyes over 24 mo

263 surements such as central retinal thickness (CRT), height of subfoveal sub-retinal fluid (SRF), centr

264 Central retinal thickness (CRT), ME type, and cyst size on optical coherence tomogr

265 ous access device (CVAD)-related thrombosis (CRT) is a common complication among patients requiring c

266 At the same time, CRT has been characterized as an important stress-respon

267 icantly increase the risk of POM compared to CRT.

268 is not superior and is possibly inferior to CRT alone for the treatment of LACC.

269 thophysiological processes of nonresponse to CRT in patients with DCM using endomyocardial biopsies.

270 ptimization of these factors, nonresponse to CRT may occur in one-third of patients, which has led to

271 ocardial biopsies fibrosis did not relate to CRT response.

272 ful to detect patients who do not respond to CRT and could benefit from alternative treatment.

273 d (68%), whereas 32 (32%) did not respond to CRT.

274 d of the patients with DCM do not respond to CRT.

275 n was negatively associated with response to CRT (25% of responders, 47% of nonresponders; odds ratio

276 genes are associated with a poor response to CRT in patients with DCM.

277 5% after 6 months was defined as response to CRT.

278 (HRV) cluster-randomized, controlled trial (CRT) in Matlab, Bangladesh, HRV was included in Matlab's

279 Cluster-randomized trials (CRTs) are able to address research questions that random

280 is of heart failure (HF) patients undergoing CRT device implantation.

281 cing was performed in 27 patients undergoing CRT implantation.

282 ion with POM compared to patients undergoing CRT.

283 in patients receiving de novo versus upgrade CRT defibrillator therapy.

284 It remains unclear why CRT expression is preserved by malignant cells during th

285 motherapy resulted in better compliance with CRT but worse compliance with chemotherapy compared with

286 ty was lower (37% v 27%) and compliance with CRT higher in group B (91%, 78%, and 76% v 97%, 87%, and

287 th lower LRF rates than historical data with CRT alone, toxicity was substantial, and LRF still occur

288 improve survival before moving forward with CRT and subsequent resection.This is an open access arti

289 In analyses of IECs with CRT knockdown or overexpression, we found that CRT regul

290 Thirty patients were implanted with CRT owing to reduced left ventricular ejection fraction

291 omes in CRT-eligible patients implanted with CRT-D versus ICD-only therapy among patients with NICD a

292 Patients with CRT experienced a statistically significant improvement

293 Patients with CRT had similar 2-year rates of the composite of death o

294 Patients with CRT OFF had a higher Interagency Registry for Mechanical

295 s for future relapse after interactions with CRTs.

296 ratio, 0.60 [95% CI, 0.42-0.86]) and without CRT (42.5% versus 66.9%, hazard ratio, 0.52 [95% CI, 0.3

297 also consistent in patients with and without CRT as were improvements in quality-of-life and exercise

298 es in quality of life (QoL) with and without CRT.

299 Implantation of an ICD with or without CRT.

300 hospitalization compared with those without CRT (57.6% versus 55%, P=0.32).